Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.33 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.30 |
| ▸ | AURKA | O14965 | 2/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496203 | 0.80 | BRAF (0.45) | CYP1A2 | |
| SCHEMBL2616774 | 0.80 | PDK2 (0.36) | ADORA2AADORA2B | |
| SCHEMBL1496216 | 0.78 | PDPK1 (0.43) | RETLRRK2PI4KAXDHPI4K2B | |
| SCHEMBL1496247 | 0.78 | BRAF (0.39) | MAPK1 | |
| SCHEMBL23063609 | 0.77 | CHEK1 (0.38) | ADORA2AADORA2BGSK3BGSK3AMAPK1 | |
| SCHEMBL1593590 | 0.77 | JAK2 (0.37) | RETLRRK2PI4KAXDHPI4K2B | |
| SCHEMBL18552941 | 0.77 | MEN1 (0.41) | ADORA2AADORA2BCYP1A2LMNACHEK1 | |
| SCHEMBL20247407 | 0.77 | BRD4 (0.34) | ADORA2AADORA2BGSK3BGSK3AMAPK1 | |
| SCHEMBL18921901 | 0.77 | CDK9 (0.35) | RETLRRK2PI4KAXDHPI4K2B | |
| SCHEMBL14070089 | 0.77 | GRM4 (0.39) | ADORA2AADORA2BGSK3BGSK3ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596074-B1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2022-12-14 | — | — | EP | disclosed |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA | 2021-04-06 | — | — | US | disclosed |
| US-20200369663-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2020-11-26 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10745407-B2 | Heterocyclic derivatives for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2020-08-18 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| WO-2018167690-A1 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2018-09-20 | — | — | WO | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-20080096913-A1 | PPAR active compounds | PLEXXIKON, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096913-A1 | PPAR active compounds | PLEXXIKON, INC. | 2008-04-24 | — | — | US | disclosed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7348338-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20080045581-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. | 2007-06-28 | — | — | US | disclosed |
| US-7202266-B2 | PPAR active compounds | PLEXXIKON, INC. (US) | 2007-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096913-A1 | PPAR active compounds | PPARG, PPARD, PPARA | ADORA2A 317/4885ADORA2B 1012/4885RET 3344/4885 |
| US-10745407-B2 | Heterocyclic derivatives for the treatment of cystic fibrosis | CFTR, ABCC1, ABCC5 | ADORA2A 3057/4885ADORA2B 3089/4885RET 2817/4885 |
| US-20200369663-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC1 | ADORA2A 3120/4885ADORA2B 2699/4885RET 3322/4885 |
| US-10968225-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC1 | ADORA2A 3120/4885ADORA2B 2699/4885RET 3322/4885 |
| US-20080045581-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ADORA2A 317/4885ADORA2B 1012/4885RET 3344/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | ADORA2A 3806/4885ADORA2B 3292/4885RET 282/4885 |
| US-20070149603-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ADORA2A 317/4885ADORA2B 1012/4885RET 3344/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ADORA2A 3784/4885ADORA2B 3226/4885RET 275/4885 |
| US-20070155818-A1 | PPAR ACTIVE COMPOUNDS | PPARG, PPARD, PPARA | ADORA2A 317/4885ADORA2B 1012/4885RET 3344/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | ADORA2A 3784/4885ADORA2B 3226/4885RET 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.